Metabolomics Characterization of Biomarkers of Different Types of Myocardial Infarction in Different Time.

Myocardial Infarction Clinical Trial

— MCBDTMIDT  

Official title:

Metabolomics Characterization of Biomarkers of Different Types of Myocardial Infarction in Different Time.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04817748
• Other study ID #: MCBDTMIDT
• Status: Recruiting
• Start date: November 17, 2020
• Est. completion date: May 1, 2021

Study information

• Verified date: March 2021
• Source: Shanghai 10th People's Hospital
• Contact: Yi Zhang, MD
• Phone: 18917686332
• Email: yizshcn[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To find new biomarkers through Metabonomics Study of different types of myocardial infarction in Different Time.

Description:

In recent years, with the deepening understanding of the mechanism of myocardial infarction, in addition to the early understanding of plaque rupture, plaque erosion and other mechanisms, studies have found that inflammation, immunity, metabolism and other factors also play an increasingly important role in the occurrence and development of myocardial infarction. The LoDoCo2 study published at the 2020 ESC annual meeting and the COLCOT study previously published confirmed for the first time the therapeutic effect of anti-inflammatory drug colchicine in chronic coronary disease and acute myocardial infarction. At the same time, the fourth international definition of myocardial infarction also defines three different types of acute ST segment elevation myocardial infarction (STEMI), acute non ST segment elevation myocardial infarction (NSTEMI) and non infarct acute myocardial infarction (MINOCA). However, there are no clear research results on the mechanism, especially the mechanism of MINOCA. Therefore, the study of acute myocardial infarction in three groups is of great significance.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: May 1, 2021
• Est. primary completion date: May 1, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 76 Years

Eligibility

Inclusion Criteria:

1.The patient clearly had acute myocardial infarction. 2.The patient's serum cardiac markers (mainly troponin) were elevated (at least above the upper limit of 99% reference value) and accompanied by one of the following clinical indicators:

1. Ischemic symptoms

2. New ischemic ECG changes, new ST-T changes or left bundle branch block(LBBB).

3. Pathological Q wave formation in ECG

4. Imaging evidence showed new loss of myocardial activity or new regional wall motion abnormalities.

5. The thrombus was confirmed by coronary angiography. 3.The patient had chest pain symptoms, but coronary angiography showed normal coronary artery (such as intercostal neuralgia, cervical spondylosis, chest pain of unknown origin, etc.)

Exclusion Criteria:

1. Refusal to sign informed consent.

2. Surgical treatment was performed in the last three months.

3. Patients with a history of the following diseases or consider the diagnosis of the following diseases:Stress cardiomyopathy, myocarditis, pericarditis, pneumonia, pulmonary embolism, aortic dissection.

4. Severe heart failure, grade IV cardiac function.

5. Liver and kidney dysfunction.

6. blood-borne diseases, including HIV / AIDS, hepatitis B, hepatitis C, etc.

7. Patients with a history of malignancies, autoimmune diseases, severe infectious diseases and trauma.

8. Previous history of myocardial infarction and stroke.

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction

Locations

Country	Name	City	State
China	Yi Zhang	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai 10th People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	metabolites molecules	Detection of small molecular metabolites in blood by liquid chromatography mass spectrometry and gas chromatography mass spectrometry	6 months